Drug Profile
Research programme: lactosylceramide synthase inhibitors - Amalyte Pharmaceuticals
Alternative Names: AM1101Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Amalyte Pharmaceuticals
- Class Small molecules
- Mechanism of Action UDP galactose-glucosylceramide galactosyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Age-related macular degeneration; Polycystic kidney disease; Vascular restenosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Polycystic-kidney-disease in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Vascular-restenosis in USA